Investor Presentaiton

Investor presentation Full year 2018 Slide 83 PIONEER programme completed for oral semaglutide and global trials showed consistent efficacy profile PIONEER 1 2 3 4 5 7 8 Baseline 8.0% 8.1% 8.3% 8.0% 8.0% 8.3% 8.2% Change in HbA1c (%) Baseline Change in -0.8 -0.1 -0.1 -0.1 -0.5 -0.8 -0.6 -0.7 -1.0 -0.9 -1.1 -1.3 -1.1 -1.4 -1.4 -1.4 -1.4 -1.5 -1.3 -1.1 88 kg 92 kg 91 kg 94 kg 91 kg 89 kg 86 kg 0.6 weight (kg) -1.7 -1.5 -2.5 -0.7 -0.1 -1.0 -3.8 -0.8 -1.2 -1.1 -2.2 -3.2 -4.2 -4.1 oral semaglutide 3 mg oral semaglutide 7 mg -2.9 -4.3 -2.9 -3.3 -3.7 -4.7 oral semaglutide 14 mg placebo empagliflozin 25 mg Sitagliptin 100 mg Victoza 1.8 mg Note: PIONEER 9 and PIONEER 10 were Japanese studies and PIONEER 6 was a CV safety study. Statistically significant; PIONEER 1: QD oral sema versus placebo in subjects with T2D treated with diet and exercise only; PIONEER 2: QD oral sema versus empagliflozin 25 mg in subjects with T2D; PIONEER 3: QD oral sema versus sitagliptin 100 mg in subjects with T2D; PIONEER 4: QD oral sema versus Victoza® 1.8 mg and placebo in subjects with T2D; PIONEER 5: QD oral sema versus placebo in subjects with T2D and moderate renal impairment; PIONEER 7: QD oral sema using a flexible dose adjustment based on clinical evaluation versus sitagliptin 100 mg in subjects with T2D; PIONEER 8: Effects of QD oral sema versus placebo in subjects with long duration of T2D treated with insulin ER: Extended-release; QW: once weekly; QD: once daily; oral sema: oral semaglutide; T2D: type 2 diabetes, OAD: oral anti-diabetics novo nordisk

View entire presentation